Eye Drops That Restore Sight? Meet the Light-Activated Molecules Giving Blind Mice Their Vision Back

For people living with blinding diseases like age-related macular degeneration or retinitis pigmentosa, the damage usually starts in one specific place: the photoreceptors, the light-detecting cells lining the retina. Once these cells degenerate, the rest of the visual system, the neurons that carry signals to the brain, is often still intact. It’s just left waiting for a signal that never arrives.

A team led by the Institute for Bioengineering of Catalonia (IBEC) in Barcelona thinks they’ve found a way to give that signal back, without touching a single gene or implanting any hardware.

The researchers developed a new family of molecules called prosthe6, built using a technique known as photopharmacology, essentially, chemistry that can be switched on and off with light. These photoswitchable compounds are designed to mimic what dying photoreceptors normally do: convert incoming light into a signal the retina’s remaining circuitry can use.

In mice that were completely blind, the results were striking. Healthy mice instinctively avoid brightly lit spaces and prefer the dark, a behavior that depends entirely on being able to see. Blind mice lose this preference completely, wandering indifferently between light and dark. After treatment with prosthe6, that instinct came back on its own, with no training involved, under everyday lighting conditions comparable to an overcast day indoors.

Two compounds in particular, prosthe6-12 and prosthe6-15, stood out, and not just for how well they worked. They restored light-driven behavior whether injected directly into the eye or simply applied as eye drops, hours after treatment, with no signs of pain, distress, or structural changes to the eye.

That detail matters enormously. Gene therapies and retinal implants, the leading experimental approaches to blindness so far, are invasive, expensive, and often limited to very specific genetic causes. A drug you could administer as eye drops would sidestep nearly all of that, at least in principle.

It’s still early-stage work, done in mice, and the compounds now need to prove themselves safe and effective for extended use before anything resembling a human trial is possible. But with an estimated 200 million people worldwide affected by photoreceptor-degenerating diseases, a spin-off company is already forming to push this technology toward the clinic.

Sometimes the most elegant solution to “the wiring still works, the sensor doesn’t” isn’t to rebuild the sensor. It’s to hand the wiring something new to listen to.

Original paper: Sortino et al. (2026), Restoration of saccadic eye movements and visually guided behavior in ambient white light with photoswitchable small molecules, Journal of the American Chemical Society. DOI: 10.1021/jacs.5c18611 

Source: Eye Drops That Restore Sight? Meet the Light-Activated Molecules Giving Blind Mice Their Vision Back